Covid Vaccine Race

94% of the participants in the study developed COVID-19 antibodies.

The Sinovac developed vaccine generated antibodies against SARS-CoV-2 in a phase 1/2 trial.

AstraZeneca’s COVID-19 vaccine was safe and immunogenic for people with HIV who are well-controlled on antiretroviral therapy, a study has shown.

Seqirus is seeking reactogenicity and immunogenicity outcomes between its influenza vaccines and available mRNA vaccines for COVID-19.

Plus: how could the COVID-19 testing market boom improve public flu awareness?

As many vaccines are under Emergency Use Authorization (EUA), understanding the incidence rates of adverse events is critical to providing education and awareness, while working to increase distribution.

An interview with a study author on new Novavax-Seqirus co-administration trial data, and the future concerns of circulating COIVD-19 and influenza.

With a small number of heart-related adverse effects in younger people, the US Food and Drug Administration (FDA) will move towards a warning statement for Pfizer and Moderna vaccines.

A new report from a Qatari pilot program showed vaccines are highly effective against COVID-19, but they do not completely eliminate risk.

The benefits of mRNA vaccinations were determined to still clearly outweigh the risks in adolescents and young adults.

According to a small study, the Moderna and Pfizer COVID-19 vaccines do not impact male fertility.

Africa sees third wave as only 1% of the population is fully vaccinated.

CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity.

Investigators in Brazil attribute Trichosporon asahii fungemia in critically ill COVID-19 patients to “overexposure” to antibiotics and corticosteroids.

A discussion surrounding Novavax’s NVX-CoV2373 with Lisa Dunkle, MD.

With the company reporting its data today and it applying for authorization with regulatory bodies internationally, and later this year with the US Food and Drug Administration (FDA), what does the prospect of this new vaccine mean to people in the US and internationally?

India plans to manufacture over 2 billion doses of COVID-19 vaccines by December

Experts suggest the vaccine, if regulated by the FDA, would benefit the US as a booster dose to combat waning immunity against emerging variants.

A Q&A surrounding the two technologies with investigators from the Wistar Institute.

The federal agency has asked Johnson & Johnson to discard its COVID-19 vaccine made at a plant in Baltimore.

The committee members discussed their concerns about having sufficient data to make an informed decision around the risk vs. benefits for looking at potential FDA approvals for vaccines in this population group.

The extension changes the shelf life from 3 months to 4.5 months.

The company’s submission is for teens 12-17 years old and is based on data from its phase 2/3 trial studying its mRNA-1273 vaccine.

The agreement brings the total number of doses bought by the United States to 800 million.

Hesitancy is a hurdle we have been struggling with in general when it comes to vaccines, but even more so when it comes to COVID-19. Throw politicization and the nuances of EUA into this mix, and it’s not surprising we’re having to work exceedingly hard to expand vaccine uptake.

Deaths continue to plunge in Brazil as more vaccinations are administered.

A county-level study of COVID-19 vaccination rates by the US Centers for Disease Control and Prevention (CDC) reveals substantially lower rates in rural than in urban areas in the US.

Worries mount in Africa as only 2% of the population has received a vaccine.

The newest data for the real-world assessment show the mRNA vaccine provides greater immunogenicity in persons aged 12-15 years old than in young adults.